某“三甲”医院Ⅰ类切口手术围术期预防使用抗菌药物调查分析
x

请在关注微信后,向客服人员索取文件

篇名: 某“三甲”医院Ⅰ类切口手术围术期预防使用抗菌药物调查分析
TITLE:
摘要: 目的:为Ⅰ类切口手术围术期合理预防使用抗菌药物提供参考。方法:随机抽取某“三甲”医院2013年3月-2015年2月Ⅰ类切口手术患者4 201例,对Ⅰ类切口手术围术期预防使用抗菌药物进行回顾性分析。结果:在4 201例Ⅰ类切口手术患者中,预防使用抗菌药物2 399例(占57.10%)。预防使用抗菌药物以头孢菌素、β-内酰胺类/β-内酰胺酶抑制剂为主,分别占45.60%、19.76%;头孢唑林、头孢曲松、阿莫西林钠克拉维酸钾的使用频次位于前3名。其中,预防用药时机不适宜的频数为823(占34.31%),预防用药疗程>48 h的频数为855(占35.64%)。结论:该院Ⅰ类切口手术围术期预防使用抗菌药物不合理情况仍然存在,应加强抗菌药物的监管,定期进行抗菌药物合理使用专题讲座学习,以促进抗菌药物的临床合理使用。
ABSTRACT: OBJECTIVE: To provide reference for perioperative rational prophylactic application of antibacterials in type Ⅰ incision operation. METHODS: 4 201 patients underwent type Ⅰ incision operation were collected from a class A grade three hospital during Mar. 2013-Feb. 2015. The perioperative prophylactic application of antibacterials in type Ⅰ incision operation were analyzed statistically. RESULTS: Of 4 201 patients underwent type Ⅰ incision operation, there were 2 399 cases of prophylactic application of antibiotics (accounting for 57.10%). Cephalosporins and β-lactam/β-lactamase inhibitor were the main classes of antibacterials for preventive use, accounting for 45.60% and 19.76%, respectively. The frequency of using cefazolin, ceftriaxone and amoxicillin-clavulanic acid ranked the top 3 places, among which there was 823 cases of unsuitable prophylactic medication time (34.31%), and 855 cases of prophylactic medication time >48 h (accounting for 35.64%). CONCLUSIONS: There still is unreasonable perioperative prophylactic application of antibacterials in type Ⅰ incision operation in this hospital. It is necessary to strengthen the supervision of antibacterials and conduct regular rational antibacterials use seminars in order to promote rational use of antibacterials.
期刊: 2016年第27卷第8期
作者: 李慧兰,朱苗苗,张佩,张赞玲
AUTHORS: LI Huilan,ZHU Miaomiao,ZHANG Pei,ZHANG Zanling
关键字: Ⅰ类切口手术;围术期;抗菌药物;预防用药;合理用药
KEYWORDS: Type Ⅰ incision optration; Perioperative; Antibacterials; Prophylactic medication; Rational drug use
阅读数: 311 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!